News
Geneva, Switzerland, October 20, 2022 – AMAL Therapeutics is pleased to announce that the latest findings of its research team is online on the Cancers website.
Geneva - September 1st, 2022 - Laetitia Devy Dimanche is taking over CEO position from Madiha Derouazi
Geneva - 21 June 2022 - Congratulations to Madiha Derouazi & Elodie Belnoue for winning the "SMEs" category at the European InventorAward 2022!
Geneva, 17 May 2022 – We are very happy and proud to announce that Madiha Derouazi and Elodie Belnoue have been jointly nominated for the EPO's European Inventor Award 2022.
AMAL Therapeutics and ViraTherapeutics, in partnership with their common parent company, Boehringer Ingelheim, are very proud to announce that they have advanced their first-in-class heterologous prime-boost vaccine to Phase 1 studies in patients with colorectal cancer in combination with Ezabenlimab (BI 754091).
Pages
- 1
- 2